Dihydroartemisinin/piperaquine

Drug Profile

Dihydroartemisinin/piperaquine

Alternative Names: Artekin; Eurartekin; Eurartesim; Piperaquine/dihydroartemisinin

Latest Information Update: 03 Dec 2015

Price : $50

At a glance

  • Originator Chongqing Holley; Medicines for Malaria Venture; sigma-tau SpA; University of Oxford
  • Developer Medicines for Malaria Venture; sigma-tau SpA
  • Class Antimalarials; Artemisinins; Piperazines; Quinolines; Sesquiterpenes
  • Mechanism of Action Free radical stimulants; Hemozoin inhibitors; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malaria
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malaria

Most Recent Events

  • 03 Dec 2015 The Medicines for Malaria Venture announces intention to submit the dispersible paediatric formulation to the EMA in the second quarter of 2015
  • 08 Jul 2015 Sigma-tau SpA completes its phase II trial in Malaria (In infants) in Tanzania, Congo, Mozambique, Gambia and Burkina Faso (NCT01992900)
  • 02 Jul 2015 Registered for Malaria in Kenya, Nigeria and Zambia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top